Clinical Trial Update: Prospective Registry Investigating Maternal and Infant Outcomes in Anifrolumab Users

View source ↗

Summary

Prospective registry evaluating maternal and infant outcomes in pregnant individuals exposed to anifrolumab for systemic lupus erythematosus.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• SAPHNELO (ANIFROLUMAB-FNIA)

Snippet

Sponsor: AstraZeneca | Conditions: Systemic Lupus Erythematosus | Status: RECRUITING